Emerging evidence suggests that the clinical success of conventional chemotherapy is not solely attributed to tumor cell toxicity, but also results from the restoration of immunosurveillance, which has been largely neglected in the past preclinical and clinical research. Antitumor immune response can be primed by immunogenic cell death (ICD), a type of cell death characterized by cell-surface translocation of calreticulin (CRT), extracellular release of ATP and high mobility group box 1 (HMGB1), and stimulation of type I interferon (IFN) responses. Here we summarize recent studies showing conventional chemotherapeutics as ICD inducers, which are capable of modulating tumor infiltrating lymphocytes (TILs) and reactivating antitumor immunity within an immuno-suppressive microenvironment. Such immunological effects of conventional chemotherapy are likely critical for better prognosis of cancer patients. Furthermore, combination of ICD-inducing chemotherapeutics with immunotherapy is a promising approach for improving the clinical outcomes of cancer patients.

https://doi.org/10.1016/j.gendis.2018.05.003
Introduction

Cancer was previously thought to be a cell-autonomous disease. This cancer cell-centric perspective has been significantly modified recently by incorporation of the concept of immunosurveillance, largely due to the recent success of immunotherapy with immune checkpoint blockers (ICBs).\textsuperscript{1-4} It is now clear that naïve tumor cells can be effectively eliminated by the immune system except for tumor metastasis.\textsuperscript{1,2,5,6} Under the immunological stress from CD4\textsuperscript{+} T lymphocytes, type I helper (Th1) CD4\textsuperscript{+} T lymphocytes, and natural killer (NK) cells. The escape phase is characterized by diminishing of immune infiltrates and accumulation of cells that suppress anticancer immunity, such as regulatory T cells (Tregs) and immunosuppressive myeloid cells.\textsuperscript{6} These alterations reflect the ability of tumors to generate immunosuppressive signals and foster immunosuppressive cells in the TME.

In anticancer immune response, CTLs utilize T cell receptor (TCR) and CD8 to recognize antigens presented by major histocompatibility complex (MHC) class I molecules on the plasma membrane of tumor cells, leading to release of perforin-1 (PRF1) and granzyme B to induce cytotoxicity.\textsuperscript{7} CTLs also suppress tumor growth by releasing interferon-γ (IFNγ), an immuno-stimulatory cytokine.\textsuperscript{10} Th1 CD4\textsuperscript{+} T lymphocytes recognize antigens presented by MHC class II molecules on the plasma membrane of target cells through TCR and CD4, and release a variety of immuno-stimulatory cytokines such as IFNγ and interleukin-2 (IL-2).\textsuperscript{11} Upon the activation of NK cells, cancer cells lose inhibitory signals and present ligands to NK cell-activating receptors including CD226 and KLRK1 (killer cell lectin-like receptor subfamily K, member 1).\textsuperscript{12} CTLs and Th1 CD4\textsuperscript{+} T lymphocytes are actively involved in local immunosurveillance, while NK cells primarily defend against tumor metastasis.\textsuperscript{12} Under the immunological stress from CTLs, target cells lose the expression of MHC class I molecules and become vulnerable to NK cells. An optimal TME is infiltrated by a mixture of CTLs, Th1 CD4\textsuperscript{+} T lymphocytes and NK cells.

An effective antitumor immune response is often triggered by a combination of lymphocytes and a subset of dendritic cells (DCs).\textsuperscript{2,13} CD8\textsuperscript{+}CD134\textsuperscript{+} DCs first engulf fractions of cancer cells, process them, and then present tumor-associated antigens to CTLs, leading to cross-priming of CD8\textsuperscript{+} T cells and anticancer immunity.\textsuperscript{15} In addition, DCs have a crucial immuno-modulatory effect on Th1 CD4\textsuperscript{+} T lymphocytes and NK cells.\textsuperscript{16} Accumulating evidence suggests that reactivation of immunosurveillance is critical for better prognosis and improved patient survival, which can be achieved by using agents that induce immunogenic cell death in tumor cells.

Immunogenic cell death in cancer cells

Immunogenic cell death (ICD) is a type of tumor cell death which primes an anticancer immune response.\textsuperscript{17} A variety of chemotherapeutic agents can induce ICD, as indicated by the alterations in TIL abundance and composition, which is a marker of favorable prognosis.\textsuperscript{7} For example, in response to anthracyclines or oxaliplatin treatment, breast and colorectal cancer patients have increased numbers of TILs and higher ratio of CD8\textsuperscript{+} CTLs vs. FOXP3\textsuperscript{+} Tregs, leading to favorable therapeutic response.\textsuperscript{18-22} ICD is defined by two criteria. First, tumor cells succumbing to ICD in vitro without any adjuvant can trigger antitumor immunity that protects mice against a subsequent challenge with live tumor cells of the same type.\textsuperscript{17} Second, ICD induced in vivo can stimulate local antitumor immunity, which is characterized by attracting immune effector cells into the TME, leading to tumor suppression that at least partially relies on the immune system.\textsuperscript{23,24} In response to ICD-inducing chemotherapeutics, tumor cells expose CRT on cell surface prior to death, and release damage-associated molecular pattern (DAMP) molecules such as ATP during apoptosis or HMGB1 upon secondary necrosis. These DAMPs stimulate the recruitment of DCs into the tumor bed, the uptake and processing of tumor antigens, and the optimal antigen presentation to T cells. Cross-priming of CD8\textsuperscript{+} CTLs is triggered by mature DCs and γδ T cells in an IL-1β- and IL-17-dependent manner. Primed CTLs then elicit a direct cytotoxic response to kill remaining tumor cells through the generation of IFNγ, perforin-1 and granzyme B (Fig. 1). Therefore, the hallmarks of ICD include calreticulin (CRT) plasma-membrane translocation, extracellular ATP and/or HMGB1 release, and stimulation of type I interferon (IFN) responses.\textsuperscript{25-28}

Cell-surface CRT as a key pro-phagocytic signal

ICD induced by chemotherapeutics often involves endoplasmic reticulum (ER) stress, which promotes translocation of CRT from ER lumen to the outer leaflet of plasma membrane.\textsuperscript{29,30} This occurs prior to membrane exposure of phosphatidylethanolamine (PS), a marker of apoptosis.\textsuperscript{30} Upon treatment with the ICD-inducing chemotherapeutics such as anthracyclines or oxaliplatin, ER stress is initiated through
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by PKR-like ER kinase (PERK). This leads to subsequent signaling events including caspase-8-dependent proteolysis of the ER protein BAP31, activation of pro-apoptotic proteins BAX and BAK, translocation of CRT from the ER to Golgi apparatus, and exocytosis of CRT-containing vesicles, eventually leading to SNARE-mediated relocation of CRT onto cell surface.30 Production of reactive oxygen species (ROS) and nitric oxide facilitates the anthracycline-induced CRT exposure.30,31

CRT exposure is essential as an ER immunogenic signal for the induction of tumor-associated immune responses.28 Pharmacological or genetic inhibition of the ER stress response pathway abrogates CRT translocation and attenuates the immunological effects of cytotoxic chemotherapeutics.30 Suppression of CRT exposure and ICD also abolishes the activity of dying tumor cells as a vaccine to trigger an anticancer immune response.29,30,32 Conversely, administration of recombinant CRT to the plasma membrane of cells treated with a non-ICD inducer (e.g., cisplatin) could reinstate ICD.30,32 CRT is functionally considered as an "eat-me" signal to the immune system. Cells with CRT expression on their surface can be recognized and engulfed by CD91+ cells (e.g., DCs and macrophages), unless they simultaneously express a "don't-eat-me" signal (e.g., CD47). CRT acts on target DCs via CD91 expressed on their surface to promote the release of pro-inflammatory cytokines (e.g., TNF-α and IL-6) and modulate the activity of type 17 helper T (Th17) cells in an immunosuppressive tumor bed. The binding of CRT to CD91 also facilitates the recruitment of antigen-presenting cells (e.g., DCs) into the tumor bed, engulfment of tumor cells by DCs, and optimal antigen presentation to T cells, eventually leading to activation of the immune system.34 Clinical evidence suggests a correlation between disease outcomes and CRT cell-surface translocation and CD47 surface expression in cancer cells. For example, deficient CRT exposure in colorectal tumor cells is associated with loss of TILs and poor prognosis.35 CRT expression and lack of CD47 expression on the surface of acute myeloid leukemia (AML) cells are associated with favorable anticancer immune response and higher survival rate in AML patients.36 Furthermore, CRT expression accompanied by CD47 exposure on the membrane of cancer cells is correlated with poor prognosis of neuroblastoma, bladder cancer and mantle cell lymphoma patients.37 Collectively, these findings indicate that CRT cell-surface translocation is a key event in ICD-mediated activation of the immune response.

**ATP release**

ATP secretion from tumor cells can also trigger an immune response, and is often associated with autophagy, a normal physiological process in response to stress or nutrients deprivation.23,38 During autophagy, cytoplasmic content is sequestered into double-membraned organelles through a series of ordered events, including formation of autophagosomes, lysosomal fusion, and cargo digestion, which allow recycling of building blocks of cells into energy...
metabolic/anabolic reactions. Blocking autophagy by a pharmacological or genetic approach limited extracellular release of ATP without affecting either CRT translocation or HMGB1 secretion, and resulted in poor recruitment of macrophages and DCs, compromised anticancer immunity and unfavorable antitumor response. Autophagy has an antitumor effect and is often suppressed in tumor cells. Autophagy-deficient tumors exhibited reduced ATP secretion and TILs in response to chemotherapy, further suggesting that autophagy suppression can be utilized by malignant cells to evade immunosurveillance.

The level of extracellular ATP in response to chemotherapy is affected not only by autophagy, but also by ectonucleotidases (e.g., CD39 and CD73). CD39 catalyzes ATP hydrolysis, and the resulting products (e.g., ADP and AMP) are further hydrolyzed to immunosuppressive adenosine. This resulted in an extremely low level of ATP in the extracellular milieu. TILs expressing CD39 (e.g., Treg and Th17 cells) have been shown to blunt immune response and promote tumor growth. Interestingly, CD39/CD73-transfected cancer cells were refractory to chemotherapy or immunotherapy, which can be overcome by CD73-blocking antibodies that restore the activity of CD3\textsubscript{47} T lymphocytes.

Extracellular ATP liberated from dying tumor cells generates a strong "find-me" signal for DCs and macrophages, upon its binding to P2Y2 receptors expressed on the surface of the target cells. In line with this notion, administration of ATP\textsubscript{Y5}, an ATP analog that cannot be metabolized by CD39 and CD73, leads to the recruitment of DCs in a P2Y2-dependent manner. Extracellular ATP not only attracts immune cells into the tumor bed, but also modulates their activity. For example, ATP can induce the maturation of myeloid-derived DCs, which is accompanied by increased expression of CD40, CD80, CD83, and CD86, and also promote macrophage expansion through formation of lamellipodial membrane protrusions.

**HMGB1 release**

HMGB1 is released from dying cells that are undergoing necrosis including programmed necrosis (necroptosis), as well as from immune cells that recognize pathogens. Upon its release, HMGB1 triggers a strong inflammatory response, and inhibition of HMGB1 using blocking antibodies or siRNAs suppressed anthracycline-induced anticancer immunity. In this context, HMGB1 activates DCs and stimulates an optimal presentation of tumor-associated antigens to T cells, upon its binding to P2Y4. TLR4 is associated with ICD signaling, and inactivation of TLR4 diminished the DC-based cross-presentation of cancer-associated antigens and caused immune deficiency. RAGE (receptor for HMGB1) binds to its RAGE receptor protein and essential anti-phagocytic signal, as a potential negative regulator of ICD. The inhibitory effect of CD47 on phagocytosis is mediated by its binding to signal-regulatory protein \(\alpha\) (SIRP\(\alpha\)), which is expressed on macrophages and DCs. CD47 is expressed in all human solid tumor cells and protects them from being recognized and cleared by innate immunosurveillance. High CD47 mRNA expression is associated with poor survival of cancer patients. CD47 blockade by antibodies has been explored in various preclinical models, and is also being tested in multiple ongoing clinical trials. Recent findings indicate that the CD47-SIRP\(\alpha\) signaling pathway determines the clearance of cytosolic DNA in DCs, and anti-CD47 antibodies suppress cytosolic DNA degradation, leading to activation of the cGAS-STING-IRF3 pathway and adaptive antitumor immunity.

Recent studies have revealed the mechanisms and upstream regulators that contribute to upregulation of CD47 in cancer cells. It was shown that the TNF/NF-\(\kappa\)B pathway directly regulates CD47 in breast cancer cells through a CD47-associated super-enhancer. CD47 could also be upregulated by hypoxia-inducible factor 1 (HIF-1) in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. CD47 oncoprotein was found to upregulate CD47 and PD-L1 expression by directly binding to their promoters, and \(\kappa\)-MyC depletion decreased the expression of CD47 in a variety of tumor cell lines. In addition, c-MyC can mediate immune escape by directly binding to the STAT1 promoter to suppress the type I and type II IFN response, as well as by indirectly reducing the secretion of IFN\(\gamma\). Inactivation of oncogenes such as c-MyC often induces tumor cell death with features of ICD, and represents a promising strategy to elicit antitumor immunity. A number of chemotherapeutic agents can downregulate c-MyC, which may restore antitumor immune response and promote remodeling of the TME.

**Induction of ICD by cytotoxic chemotherapeutics**

Conventional cytotoxic chemotherapeutics are generally classified according to their mechanisms of action: (1) alkylating agents that elicit inter- and intra-strand DNA crosslinks that destabilize DNA during replication (e.g., cyclophosphamide and oxaliplatin); (2) antimitototics that disrupt DNA and/or RNA synthesis (e.g., 5-fluorouracil, gemcitabine, and mitoxantrone); (3) topoisoformer inhibitors that interfere with the DNA unwinding process during DNA replication and transcription (e.g., irinotecan); (4) microtubule poisons that inhibit tubulin polymerization/depolymerization and cause mitotic arrest (e.g., paclitaxel); (5) cytotoxic antibiotics that kill cancer cells via excessive production of ROS and DNA intercalation (e.g., anthracyclines and bleomycin). The immunogenic effects of these agents were largely neglected in previous studies that mostly utilized cell culture and immune-deficient animal models. In the past, promising anticancer agents were often moved forward into clinical trials without a thorough analysis of their immune modulatory effects. Most attention was paid to the common side effects of myelosuppression and lymphopenia of conventional chemotherapy,
| Conventional chemotherapeutics | Major targets | ICD-associated DAMPs | Clinical use | Evidence of antitumor immunity |
|--------------------------------|---------------|----------------------|--------------|-------------------------------|
| Cylophosphamide                | DNA and RNA   | Cell-surface CRT,    | Lymphomas, brain cancer, leukemia, and some solid tumors | Deplete Treg cells, favor the expansion of NK cells and stimulate DCs to produce IL-12 |
|                                |               | HMGB1 and ATP secretion |             |                               |
| Oxaliplatin                    | DNA and RNA synthesis | Cell-surface CRT, | Colorectal cancer | Increase the CTL/Treg cell ratio, deplete MDSCs, and improve the activity of neutrophils and macrophages |
|                                |               | HMGB1 and ATP secretion | |                               |
| 5-FU                           | Thymidylate synthase inhibitor | DNA replication | Colorectal, breast cancer, GIST | Increase the frequency of tumor-infiltrating CTLs, and deplete circulating MDSCs |
|                                |               | HMGB1 and ATP secretion | |                               |
| Gemcitabine                    | DNA replication | DNA replication | NSCLC, pancreatic, bladder, breast cancer | Stimulate cross-priming of CTLs, increase the number of immunostimulatory TAMs, and deplete circulating MDSCs |
|                                |               | HMGB1 and ATP secretion | |                               |
| Mitoxantrone and anthracyclines | DNA and RNA synthesis, topoisomerase II, ROS | Cell-surface CRT and ERP57, HMGB1 and ATP secretion | Leukemias, Hodgkin’s lymphoma breast, colon, lung cancer and so on | Increase the CTL/Treg cell ratio, and deplete circulating Treg cells |
| Bleomycin                      | DNA strand breaks, ROS | Cell-surface CRT and ERP57, Cell-surface HSP90 | Testicular cancer, ovarian cancer, Multiple melanoma, mantle cell lymphoma | Stimulate ICD |
| Bortezomib                     | 26S proteasome | | | Stimulate ICD |

Abbreviations: ICD, immunogenic cell death; DAMPs, damage-associated molecular patterns; ROS, radical oxygen species; CRT, calreticulin; CTL, cytotoxic T lymphocytes; Treg, regulatory T cells; NK, natural killer; DCs, dendritic cells; IL-12, interleukin-12; HMGB1, high-mobility group protein B1; ATP, adenosine triphosphate; HSP, heat-shock protein; MDSCs, myeloid-derived suppressor cells; TAMs, tumor-associated macrophages.
Chemotherapy induces immunogenic cell death

other than chemotherapy-induced antitumor immune response. Accumulating evidence indicates that the clinical success of chemotherapy is not solely attributed to tumor cell toxicity, but also the restoration of immunosurveillance (Table 1). It is now clear that a subset of chemotherapeutics can elicit the immunogenicity of tumor cells and modulate the density, composition, distribution and function of TILs, to influence prognosis and differential therapeutic responses in cancer patients. For example, chemotherapy-induced phosphorlation of p53 upregulates the NKG2D ligands presented on the membrane of target tumor cells, improving their recognition by NKG2D+ NK cells. Chemotherapy-induced membrane expression of heat shock proteins (e.g., HSP70 and HSP90) also contributes to immune stimulation. Although the majority of conventional chemotherapeutic agents are incapable of inducing ICD, their efficacy can be significantly improved by the co-administration of chemicals that produce ICD-associated DAMPs. Therefore, the effects on antitumor immune response need to be taken into consideration to improve chemotherapy regimens.

Alkylating agents

Alkylating agents can elicit an antitumor immune response by directly affecting the immune cells. For example, cyclophosphamide reinstated the activity of T and NK cells by abating Tregs in TME. The gram-positive bacteria of the intestinal microbiota contribute to the cyclophosphamide-induced immune stimulation in mice. Cyclophosphamide treatment also promoted translocation of gram-positive bacteria to secondary lymphoid organs via gap junctions in the intestinal epithelium, which stimulates the production of Th17 cells and secretion of IL-17 and IFNγ, resulting in potent antitumor immunity. A variety of transplantable tumors and carcinogen-induced mouse tumors were more sensitive to oxaliplatin/anthracycline treatment when growing in a syngeneic immunocompetent host, compared to an immuno-deficient host. Interestingly, agents with similar chemical structures may have very different immunological consequences. For example, oxaliplatin, but not cisplatin, is a potent inducer of ICD, and can trigger ER stress and antitumor immunity against both transplantable and oncogene-driven murine tumors. A combination of cisplatin and chemicals that cause ER stress can induce ICD.

Antimetabolites

Antimetabolites such as Mitoxantrone were found to facilitate tumor infiltration of immune cells in mouse models. Their therapeutic efficacy can be attenuated by: (1) depletion of CTLs and γδ T cells, but without an association with diminished NK cells and B lymphocytes; (2) repression of tumor-infiltrating DCs by an anti-CD11b antibody or P2RY2 inhibitors; (3) genetic or pharmacological inhibition of immuno-stimulatory cytokines (e.g., type I IFN, IFNγ, IL-1β, and IL-17) or their receptors; or (4) blockade of DAMP secretion from dying tumor cells.

Cytotoxic antibiotics

Doxorubicin markedly changes the immune infiltrate of breast tumors, and high infiltration of CTLs in breast tumors at diagnosis predicts favorable therapeutic response. The immuno-stimulatory effect of anthracyclines has been shown to result from their cytotoxicity to cancer cells through a multipronged adaptive stress response, involving autophagy, ER stress response, and type I IFN pathways. Autophagy is obligatory for dying tumor cells to release ATP that works both as a chemotactic factor for DCs. Cell-surface CRT elicited by ER stress stimulates the recognition of tumor-associated antigens and engulfment of tumor cells by DCs upon binding to CD91. In anthracycline-treated tumor cells, autocrine/paracrine type I IFN response is involved in the secretion of CXCL10, which is cheetactractor to lymphocytes. Upon binding to TLR4 and RAGE, HMGB1 released from dying tumor cells boosts the activation and maturation of DCs.

Bleomycin is a cytotoxic antibiotic glycopeptide that causes DNA damage by over-generation of ROS. It is clinically administered to patients with testicular cancer and Hodgkin’s lymphoma. Similar to anthracyclines and oxaliplatin, bleomycin is capable of eliciting ICD via ER stress response and ROS generation, which lead to membrane translocation of ER proteins (e.g., CRT and Erp57). Bleomycin-induced autophagy stimulated the release of HMGB1 and ATP from dying tumor cells. ICD induction by bleomycin reactivated the antitumor immunity mediated by CD8+ T cells. In addition, bleomycin treatment facilitates the release of transforming growth factor β (TGFβ) from dying tumor cells, leading to the spreading of FOXP3+ Tregs. Interestingly, the therapeutic efficacy of bleomycin was greatly improved by the ablation of TGFβ and/or Tregs.

Other drugs

Bortezomib is a specific inhibitor of the 26S proteasome subunit that has exhibited favorable therapeutic efficacy in
several types of cancer. Bortezomib-induced apoptosis in cancer cells generally results from the suppression of NF-kB and/or induction of unfolded protein response. The restoration of immunogenicity of bortezomib-treated dying cancer cells was initiated from the phagocytosis process between DCs and dying cancer cells, and was regulated by bortezomib-induced upregulation of HSP90 on the plasma membrane of dying cancer cells. DCs are primarily involved in the uptake and presentation of antigens from dying cells. Expansion of antitumor T cells is modulated through the cross-presentation of tumor antigens by DCs. Interestingly, addition of an HSP90 inhibitor significantly promoted bortezomib-induced apoptosis in cancer cells, but abolished immunogenicity. Therefore, HSP90 cell-surface exposure might be another important “eat me” signal of ICD in addition to CRT exposure.

Combinations of chemotherapy and immunotherapy

Understanding the immunological effects of chemotherapy has helped design a variety of combination regimens with potentially improved efficacy. For example, CTLA4 (cytotoxic T lymphocyte-associated protein 4) neutralizing antibodies can be used to increase the immuno-stimulatory effect of gemcitabine by ablating tumor-infiltrating Tregs. Such combinations can also be used to mitigate immunosuppressive effects of certain chemotherapies. For example, bleomycin induces CTL-dependent antitumor immunity, but also boosts TGFβ1-dependent spreading of immunosuppressive Tregs, which can be suppressed by co-administration of a TGFβ1 antibody. Anti-CD47 antibodies have shown promises in preclinical studies on brain, breast, colon, and ovary tumors, but are not sufficiently effective for eradicating these tumors. A combination of CD47 blockade with other therapeutic agents can enhance cell-surface CRT and/or eliminate Tregs and MDSCs. Numerous clinical trials have demonstrated the additive/synergistic effects of chemotherapy in combination with ICB-based immunotherapy. For example, the therapeutic efficacy of carboplatin or paclitaxel can be significantly increased by the co-administration of the anti-CTLA4 antibody ipilimumab in small cell lung carcinoma and NSCLC. We expect that the results of these trials will provide invaluable information on how to better combine chemotherapy and immunotherapy to improve the clinical management of cancer.

Perspectives and conclusions

Molecular mechanisms of ICD remain to be further delineated. For example, it is still unclear why p53-dependent apoptosis mediated through the intrinsic pathway is less immunogenic than that involving ER stress. Necroptosis is a highly immunogenic form of cell death. However, the functional role of necroptosis in chemotherapy has not been well defined. The interplays and crosstalk of different cell death pathways, such as apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy, in determining the immunological consequences of chemotherapy remain to be elucidated. In addition to c-Myc, the effect of other cancer drivers on ICD and the immunological effects of chemotherapy also need to be established. ICD can be induced in response to other pathological conditions, and is involved in tissue injury and damage repair. It is important to understand the differences between the chemotherapy-induced ICD in tumor cells and that involved in normal physiological process and other pathological conditions, in order to more specifically target tumor cells.

Several strategies have been explored to harness the immunological effects of chemotherapy. The immunological markers such as alterations of TIL density, composition, function and localization as the result of treatment have been increasingly recognized as a valuable predictor for clinical outcomes. The ICD hallmarks such as cell-surface CRT exposure, ATP secretion and HMGB1 release in tumor tissues have been analyzed and potentially useful as biomarkers for predicting favorable prognosis and survival of cancer patients. Combinations of markers from tumor cells and local and systemic immune response remain to be explored, and may help to improve the predictive power of applying these markers. Further defining the molecular mechanisms and biomarkers of ICD will undoubtedly help rational design of new combination regimens for improving therapeutic efficacy.

In conclusion, emerging preclinical and clinical evidence supports the concept that conventional chemotherapeutics can engage the immune system to act beyond tumor cells, which can be manipulated and will hopefully provide lasting benefits to cancer patients via enhanced and long-term immunosurveillance of minimal residual disease. It might be very useful to test promising anticancer drugs or combinations for their capability to induce ICD in immunocompetent models to boost antitumor immunity and improve therapeutic efficacy.

Conflicts of interest

There is no conflict of interest.

Acknowledgements

We apologize for not being able to cite many excellent original articles by our colleagues due to space limitation. We thank our lab members for critical reading. Research in the authors’ labs is supported U.S. National Institutes of Health grants (R01CA172136, R01CA203028 and R01CA201741 to L.Z.; U19AI068021 and R01CA215481 to J.Y.; and P30CA047904 to the UPMC Hillman Cancer Center).
Chemotherapy induces immunogenic cell death

5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
6. Shankaran V, Ikeda H, Bruce AT, et al. IFNγamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111.
7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
8. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715.
9. Anthony DA, Andrews DM, Watt SV, Trapani JA, Smyth MJ. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
10. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune community? The example of natural killer cells. Immunity. 2009;31:44–49.
11. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, West NR, Milne K, Truong PT, Macpherson N, Nelson BH. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11:293–2715.
12. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
13. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11:293–2715.
14. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, West NR, Milne K, Truong PT, Macpherson N, Nelson BH. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11:293–2715.
15. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
16. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715.
17. Anthony DA, Andrews DM, Watt SV, Trapani JA, Smyth MJ. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
18. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11:293–2715.
19. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, West NR, Milne K, Truong PT, Macpherson N, Nelson BH. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nat Rev Cancer. 2011;11:293–2715.
20. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
21. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715.
47. Muller T, Robaye B, Vieira RP, et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. *Allergy*. 2010;65:1545–1553.

48. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. *Annu Rev Immunol*. 2011;29:139–162.

49. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. *J Immunol*. 2005;174:7506–7515.

50. McCracken MN, Cha AC, Weissman IL. Molecular pathways: Disrupting the CD47-“Don’t eat me” signals. *Clin Cancer Res*. 2015;21:3597–3610.

51. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci USA*. 2012;109:6662–6667.

52. Gholamin S, Mitra SS, Feroze AH, et al. Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Sci Transl Med*. 2017;9.

53. Xu MM, Pu Y, Han D, et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. *Immunity*. 2017;47:363–373, e365.

54. Betancur PA, Abraham BJ, Yiu YY, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. *Nat Commun*. 2017;8:14802.

55. Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. *Proc Natl Acad Sci USA*. 2015;112:E6215–6223.

56. Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. *Science*. 2016;352:227–231.

57. Schlee M, Holzel M, Bernard S, et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt’s lymphoma. *Int J Cancer*. 2007;120:1387–1395.

58. Dranon F. Experimental human mouse tumour models: what can be learnt about human cancer immunology? *Nat Rev Immunol*. 2011;12:61–66.

59. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoeediting and its three component phases—elimination, equilibrium and escape. *Curr Opin Immunol*. 2014;27:16–25.

60. Anitei MG, Zeitoun G, Mlecink B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. *Clin Cancer Res*. 2014;20:1891–1899.

61. Ascierto PA, Capone M, Urba WJ, et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. *J Transl Med*. 2013;11:54.

62. Remark R, Becker C, Gomez JE, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. *Am J Respir Crit Care Med*. 2015;191:377–390.

63. Nelson BH. New insights into tumor immunity revealed by the unique generic and genomic aspects of ovarian cancer. *Curr Opin Immunol*. 2015;33:93–100.

64. Nes N, Andersen S, Valkov A, et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. *Prostate*. 2014;74:1452–1461.

65. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ*. 2014;21:15–25.

66. Romero AI, Chaput N, Poirier-Colame V, et al. Regulation of CD4(+)+NKGD2(-)+ Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering. *Cancer Res*. 2014;74:68–80.

67. Raulte DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. *Nat Rev Immunol*. 2009;9:566–580.

68. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhopakar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. *Blood*. 2007;109:4839–4845.

69. Fucikova J, Králíková P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. *Cancer Res*. 2011;71:4821–4833.

70. Bloy N, Pol J, Aranda F, et al. Trial watch: dendritic cell-based anticancer therapy. *Oncoimmunology*. 2014;3:e963424.

71. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. *Cancer Immunol Immunother*. 2007;56:641–648.

72. Vlauš S, Sacciferi F, Mignot G, et al. The intestinal microbiota modulates the antitumor immune effects of cyclophosphamide. *Science*. 2013;342:971–976.

73. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *J Exp Med*. 2005;202:1691–1701.

74. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. *Cancer Res*. 2011;71:4809–4820.

75. Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. *Nature*. 2015;521:94–98.

76. Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. *OncoGene*. 2011;30:1147–1158.

77. Menger L, Vaccelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. *Sci Transl Med*. 2012;4:143ra199.

78. Aranda F, Bloy N, Pesquet J, et al. Immune-dependent anti-neoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. *OncoGene*. 2015;34:3053–3062.

79. Yamazaki T, Hannani D, Poirier-Colame V, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. *Cell Death Differ*. 2014;21:69–78.

80. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. *Immunity*. 2013;38:729–741.

81. Ma Y, Mattarollo SR, Adjemian S, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. *Cancer Res*. 2014;74:436–445.

82. Sistigu A, Yamazaki T, Vaccelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *Nat Med*. 2014;20:1301–1309.

83. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol*. 2013;31:51–72.

84. Di Caro G, Cortese N, Castino GF, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. *Gut*. 2016;65:1710–1720.
85. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. *J Immunol*. 2003;170:4905–4913.

86. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances anti-tumor immune activity. *Clin Cancer Res*. 2005;11:6713–6721.

87. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor or immunity. *Cancer Res*. 2010;70:3052–3061.

88. Emile JF, Julie C, Le Malicot K, et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. *Eur J Cancer*. 2017;82:16–24.

89. Lim SH, Chua W, Cheng C, et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. *Anticancer Res*. 2014;34:6505–6513.

90. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. *Proc Natl Acad Sci USA*. 2012;109:2796–2801.

91. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol*. 2015;33:983–991.

92. Dresp J, Schmid E, Bauchinger M. The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. *Mutat Res*. 1978;56:341–353.

93. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrner PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. *N Engl J Med*. 1987;316:1435–1440.

94. Bugaut H, Bruchard M, Berger H, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. *PLoS One*. 2013;8:e65181.

95. Adams J. The proteasome: a suitable antineoplastic target. *Nat Rev Cancer*. 2004;4:349–360.

96. Lesterhuis WJ, Salmons J, Nowak AK, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. *PLoS One*. 2013;8:e61895.

97. Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: tumor-targeting monoclonal antibodies in cancer therapy. *OncoImmunology*. 2014;3:e27048.

98. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol*. 2012;30:2046–2054.

99. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol*. 2013;24:75–83.

100. Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. *Science*. 2015;350:328–334.

101. Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. *Biochim Biophys Acta*. 2016;1865:228–236.

102. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. *Cancer Cell*. 2015;28:690–714.